Literature DB >> 6489325

Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.

D Greenwood, S Baxter, A Cowlishaw, A Eley, G J Slater.   

Abstract

In conventional in vitro tests and an experimental bladder model ciprofloxacin proved very active against 103 strains of enterobacteria isolated from infected urine. Nalidixic acid-resistant strains were less susceptible to ciprofloxacin than nalidixic acid-sensitive strains, and the activity of the drug was reduced under acid conditions. Nevertheless, all strains were inhibited by 4 mg/l of ciprofloxacin at pH 5.5. Streptococcus spp., Staphylococcus aureus, Pseudomonas aeruginosa and Bacteroides spp. were less susceptible than enterobacteria, although most strains were inhibited by a therapeutically achievable concentration of 2 mg/l. Under conditions simulating the treatment of bacterial cystitis, changing concentrations of ciprofloxacin well within levels achievable in urine inhibited dense bacterial cultures for periods exceeding 24 hours, and surviving bacteria did not exhibit any reduction in susceptibility.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489325     DOI: 10.1007/bf01977493

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  8 in total

1.  Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.

Authors:  D Greenwood; F O'Grady
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

Review 2.  An in vitro model of the urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  J Antimicrob Chemother       Date:  1978-03       Impact factor: 5.790

3.  Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies.

Authors:  D Greenwood; F O'Grady
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

4.  Activities of newer quinolones against Legionella group organisms.

Authors:  D Greenwood; A Laverick
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

5.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

Authors:  D Greenwood; M Osman; J Goodwin; W A Cowlishaw; R Slack
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

7.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  8 in total
  1 in total

1.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.